Skip to main content

Table 3 Adjusted mean levels of FVC by quartile of inflammatory biomarkers and associations per IQR change

From: FEV1 and FVC and systemic inflammation in a spinal cord injury cohort

CRP (mg/L)

 

Q1

(0.07–0.99)

Q2

(1.00–2.41)

Q3

(2.42–6.91)

Q4

(6.92–161.56)

p-for trend

β (95% CI) L FEV1 per 5.91 mg/L CRP

p-value

N

77

78

78

78

311

311

311

Basica

4.02 (3.82, 4.23)

3.68 (3.47, 3.88)

3.42 (3.21, 3.62)

3.27 (3.07, 3.48)

<.0001

−82.09 (−126.69,-37.49)

0.0004

Fully adjusted

3.84 (3.63, 4.05)

3.65 (3.46, 3.83)

3.52 (3.33, 3.71)

3.39 (3.20, 3.59)

0.014

−65.50 (−106.61,-24.60)

0.0019

Parsimonious adjustedb

3.83 (3.64, 4.02)

3.63 (3.45, 3.82)

3.53 (3.34, 3.71)

3.40 (3.22, 3.59)

0.007

−60.22 (−99.61,-20.84)

0.003

IL-6 (pg/mL)

 

Q1

(0.30–1.26)

Q2

(1.27–2.12)

Q3

(2.13–4.44)

Q4

(4.45–46.8)

p-for trend

β (95% CI) mL FEV1 per 3.18 pg/mL IL-6

 

N

77

83

76

75

311

311

311

Basica

3.85 (3.63, 4.06)

3.69 (3.49, 3.89)

3.55 (3.33, 3.76)

3.29 (3.08, 3.50)

0.0004

−125.13 (−194.85,-55.40)

0.0005

Fully adjusted

3.73 (3.53, 3.93)

3.62 (3.44, 3.80)

3.61 (3.42, 3.81)

3.43 (3.23, 3.63)

0.0481

−77.69 (−143.93,-11.46)

0.0222

Parsimonious adjustedb

3.73 (3.54, 3.92)

3.62 (3.44, 3.80)

3.62 (3.43, 3.81)

3.42 (3.23, 3.61)

0.0307

−76.87 (−139.55,-14.19)

0.0169

  1. aAdjusted for age, sex, race, and height
  2. bAdjusted for age, sex, race, height, smoking status and pack-years, marijuana smoking status, COPD or asthma, current use of steroids and long-acting bronchodilators, level/severity of injury (LOI), and wheelchair use